Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Becton Dickinson › CEO exercised or converted 20K BDX derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 5, 2026
Reporting period Not applicable
Filed with the SEC Nov 9, 2026 CEO Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001628280-26-072360
Filed / recorded
Nov 9, 2026, 10:44 PM UTC
Added to OQRO Nov 9, 2026, 10:50 PM UTC
Data quality Verified: identifiers matched exactly
Issuer BECTON DICKINSON & CO
Reporting person Thomas E Jr Polen
Relationship Director, Officer
Officer title Chairman, CEO and President
Table Non-derivative (Table I)
Transaction date Nov 5, 2026
Acquired / disposed Acquired (A)
Shares owned after 130,402
Around the same time Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Nov 6 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 6 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Sep 14, 2026 FDA FDA device clearance: BD BBL Mueller Hinton II Broth (Cation-Adjusted); BD Difco Mueller Hinton Broth Sep 24, 2026 Layoff notice · 3750 Torrey View Court San Diego CA 92130 Layoff notice filed in CA: 85 employees Sep 25, 2026 FDA FDA device approval: Liverty TIPS Stent Graft Sep 28, 2026 FDA FDA device clearance: Phasix ST Parastomal Hernia Mesh Sep 28, 2026 Insider Officer sold ~$14K of BDX shares in the open market Oct 16, 2026 FDA FDA device clearance: BD Vacutainer® Serum Blood Collection Tubes; BD Vacutainer® Rapid Serum Tubes (RST) Oct 26, 2026 Insider Officer sold ~$15K of BDX shares in the open market Nov 5, 2026 Company filing · Form 8-K · Results Reported its results Nov 5, 2026 Insider CEO sold ~$629K of BDX shares in the open market